WHO granted Biological E phase II pre-qualification for its Novel Oral Polio Vaccine type 2, covering both drug substance and finished product made at its integrated site.

This approval allows Biological E to run end-to-end nOPV2 manufacturing at a single WHO-qualified facility rather than relying on externally supplied drug substance. That reduces supply-chain dependency and can shorten replenishment cycles for the global nOPV2 stockpile used in outbreak response. Procurement agencies can now source both substance and finished doses from the same WHO-prequalified site, increasing available qualified capacity for cVDPV2 campaign demand.